State of Wyoming’s Adaptimmune Therapeutics ADAP Stock Holding History

State of Wyoming’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-635	Closed	-$1K	–	1837
2022 Q1	$1K	Buy	635 +107	+20%	+$289	﹤0.01%	1725
2021 Q4	$2K	Sell	528 -29	-5%	-$132	﹤0.01%	1766
2021 Q3	$3K	Sell	557 -268	-32%	-$1.2K	﹤0.01%	1127
2021 Q2	$4K	Buy	+825	New	+$4K	﹤0.01%	1081

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State of Wyoming's ADAP Position: Q2 2022 in Review

State of Wyoming sold out of Adaptimmune Therapeutics (ADAP) in Q2 2022, closing a stake of 635 shares — an estimated $1K sold.

State of Wyoming first reported a position in ADAP in Q2 2021 and held it in 4 quarters. The position peaked at $4K in Q2 2021. 77 funds tracked by Wall St. Rank hold ADAP as of Q2 2022.

State of Wyoming reported no remaining Adaptimmune Therapeutics position as of Q2 2022 after selling out during the quarter.
State of Wyoming sold 635 Adaptimmune Therapeutics shares in Q2 2022, an estimated $1K.
State of Wyoming first reported a position in Adaptimmune Therapeutics in Q2 2021 and held it in 4 quarters.
State of Wyoming's Adaptimmune Therapeutics position peaked at $4K in Q2 2021.
77 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2022.

Based on State of Wyoming's 13F filing for Q2 2022, filed 15 Aug 2022.